Intravaginal mucosal or transmucosal delivery of antimigraine and antinausea drugs
First Claim
1. A mucoadhesive composition suitable for a mucosal or transmucosal vaginal delivery of an anti-migraine or antinausea drug, said composition comprising from about 0.001 to about 3000 mg of the antimigraine or antinausea drug, from about 30 to about 95% of a lipophilic or hydrophilic carrier, from about 0.1 to about 25% of a muccadhesive agent and from about 5 to about 30% of a sorption promoter.
1 Assignment
0 Petitions
Accused Products
Abstract
A method, composition and device for intravaginal mucosal or transmucosal delivery of antimigraine and/or antinausea drugs to a female subject for treatment of migraine and other diseases accompanied by or associated with nausea and vomiting. A mucoadhesive composition comprising antimigraine or antinausea drugs, mucoadhesive agent, penetration enhancer or sorption promoter and a hydrophilic or lipophilic carries. An intravaginal device for delivery of antimigraine or antinausea drugs.
55 Citations
20 Claims
- 1. A mucoadhesive composition suitable for a mucosal or transmucosal vaginal delivery of an anti-migraine or antinausea drug, said composition comprising from about 0.001 to about 3000 mg of the antimigraine or antinausea drug, from about 30 to about 95% of a lipophilic or hydrophilic carrier, from about 0.1 to about 25% of a muccadhesive agent and from about 5 to about 30% of a sorption promoter.
-
6. A method for treatment of migraine and headache, nausea or vomiting associated with chemotherapy, radiotherapy, surgery, pregnancy or menopause, said method comprising a step:
-
administering to a female subject in need of such treatment vaginally a mucoadhesive composition comprising from about 0.001 to about 3000 mg of the antimigraine or antinausea drug, from about 30 to about 95% of a lipophilic or hydrophilic carrier, from about 0.1 to about 25% of a mucoadhesive agent and from about 5 to about 30% of a sorption promoter, wherein said antimigraine drug is selected from the group of compounds consisting of ergotamine, dihydroergotamine, ergostine, butalbital, phenobarbital, acetaminophen, diclofenac sodium, ketoprofen, ketorolac, ibuprofen, prioxicam, naproxen, acetylsalicilic acid, flurbiprofen, tolfenamic acid, butorphanol, meperidine, methadone, sumatriptan, naratriptan, razatriptan, zolmitriptan, almotriptan, eletriptan, dexamethasone, hydrocortisone, isometheptene, chlorpromazine, diazepam, droperidol, valproic acid, gabapentin, topiramate and divalproex sodium, and wherein said antinausea drug is selected from the group consisting of metoclopramide, prochlorperazine, domperidone, ondansetron, tropisetron, dolasetron, nabilone, dronabinol, levonantradol, aprepitant, cyclizine, promethazine, and a combination thereof. - View Dependent Claims (7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
-
17. An intravaginal device for mucosal and transmucosal delivery of an antimigraine or antinausea drug
wherein said device is a tampon, tampon-like device, pessary, patch, ring, tablet, pad, suppository, sponge, film, foam, strip or intravaginal iontophoretic system incorporated with a mucoadhesive composition comprising antimigraine drug, antinausea drug or a combination thereof; -
wherein said device is incorporated with a mucoadhesive composition comprising from about 0.001 to about 3000 mg of the antimigraine or antinausea drug, from about 30 to about 95% of a lipophilic or hydrophilic carrier, from about 0.1 to about 25% of a mucoadhesive agent and from about 5 to about 30% of a sorption promoter, wherein said antimigraine drug is selected from the group of compounds consisting of ergotamine, dihydroergotamine, ergostine, butalbital, phenobarbital, acetaminophen, diclofenac sodium, ketoprofen, ketorolac, ibuprofen, prioxicam, naproxen, acetylsalicilic acid, flurbiprofen, tolfenamic acid, butorphanol, meperidine, methadone, sumatriptan, naratriptan, razatriptan, zolmitriptan, almotriptan, eletriptan, dexamethasone, hydrocortisone, isometheptene, chlorpromazine, diazepam, droperidol, valproic acid, gabapentin, topiramate and divalproex sodium, and wherein said antinausea drug is selected from the group consisting of metoclopramide, prochlorperazine, domperidone, ondansetron, tropisetron, dolasetron, nabilone, dronabinol, levonantradol, aprepitant, cyclizine, and promethazine, each alone or in combination with an another pharmaceutical agent or a pharmaceutically acceptable excipient; and
wherein said antimigraine or antinausea drug is released from said device following the insertion of the device into vagina. - View Dependent Claims (18, 19, 20)
-
Specification